Zynerba Pharmaceuticals Inc News Releases http://ir.zynerba.com/ Zynerba Pharmaceuticals Inc News Releases en Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-receives-new-us-patent-treatment-autism DEVON, Pa. , June 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Tue, 11 Jun 2019 07:00:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8606 Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-present-fdas-public-hearing-scientific DEVON, Pa. , May 30, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Ray Mannion , Zynerba’s Vice President of Thu, 30 May 2019 16:30:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8591 Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-announces-initiation-phase-2-trial Topline Data from the INSPIRE Trial Expected in the First Half 2020 DEVON, Pa. , May 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Wed, 29 May 2019 06:45:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8581 Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-present-jefferies-2019-global-healthcare DEVON, Pa. , May 28, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido Tue, 28 May 2019 11:30:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8576 Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-reports-first-quarter-2019-financial DEVON, Pa. , May 08, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, Wed, 08 May 2019 06:50:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8556 Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS) http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-receives-fast-track-designation-zygeltm - Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs - - Enrollment Progressing in Pivotal CONNECT-FX Trial of Zygel in FXS, with Data Expected in the Second Half of 2019 - DEVON, Pa. , May 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Mon, 06 May 2019 07:00:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8531 Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-present-2019-hc-wainwright-global-life DEVON, Pa. , April 02, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido Tue, 02 Apr 2019 10:00:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8491 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-reports-fourth-quarter-and-year-end-2018 DEVON, Pa. , March 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and year Mon, 11 Mar 2019 02:50:00 -0400 Zynerba Pharmaceuticals Inc News Releases 8461 Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-initiates-phase-2-trial-zygeltm-autism - Topline Data from BRIGHT Study Expected in the First Half 2020 - - Company Selects Zygel™ as Brand Name for ZYN002 CBD Transdermal Gel - DEVON, Pa. , March 07, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal Thu, 07 Mar 2019 07:00:00 -0500 Zynerba Pharmaceuticals Inc News Releases 8451 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol http://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-receives-new-us-patent-treatment-fragile DEVON, Pa. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Tue, 26 Feb 2019 07:00:00 -0500 Zynerba Pharmaceuticals Inc News Releases 8441